Skip to main content
SpringerLink
Log in

Hypertrophic Cardiomyopathy

  • Chapter
  • First Online:
Sports Cardiology

  • 563 Accesses

Abstract

Hypertrophic cardiomyopathy (HCM), characterized by left ventricular hypertrophy in the absence of causative loading conditions, is one of the most common inheritable cardiac diseases. Mild phenotypic expression of HCM can overlap with some of the physiological adaptive changes seen in the athlete’s heart and can present a diagnostic challenge.

HCM has been strongly associated with sudden cardiac death in athletes. As a result, individuals with HCM have traditionally been excluded from participation in most sporting endeavors. Recent data, however, highlight the risks of a sedentary lifestyle and the benefits of exercise in those with HCM. Recognizing the importance of patient-centered care and the heterogeneity of the disease expression and outcomes in HCM, decisions regarding competitive sporting participation are evolving in lower-risk individuals to an individualized shared decision-making process. This chapter explores these issues to provide a diagnostic and management framework for practitioners involved in the care of athletes with HCM.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212–60.

    Article  CAS  PubMed  Google Scholar 

  2. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.

    Article  PubMed  Google Scholar 

  3. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (young) adults. Circulation. 1995;92(4):785–9.

    Article  CAS  PubMed  Google Scholar 

  4. Basavarajaiah S, Wilson M, Whyte G, Shah A, McKenna W, Sharma S. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol. 2008;51(10):1033–9.

    Article  PubMed  Google Scholar 

  5. Sharma S, Drezner JA, Baggish A, et al. International recommendations for electrocardiographic interpretation in athletes. J Am Coll Cardiol. 2017;69(8):1057–75.

    Article  PubMed  Google Scholar 

  6. Sheikh N, Papadakis M, Schnell F, et al. Clinical profile of athletes with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2015;8(7):e003454.

    Article  PubMed  Google Scholar 

  7. Rowin EJ, Maron BJ, Appelbaum E, et al. Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. Am J Cardiol. 2012;110(7):1027–32.

    Article  PubMed  Google Scholar 

  8. Schnell F, Riding N, O’Hanlon R, et al. Recognition and significance of pathological T-wave inversions in athletes. Circulation. 2015;131(2):165–73.

    Article  PubMed  Google Scholar 

  9. Papadakis M, Carre F, Kervio G, et al. The prevalence, distribution, and clinical outcomes of electrocardiographic repolarization patterns in male athletes of African/Afro-Caribbean origin. Eur Heart J. 2011;32(18):2304–13.

    Article  PubMed  Google Scholar 

  10. Basavarajaiah S, Boraita A, Whyte G, et al. Ethnic differences in left ventricular remodeling in highly-trained athletes relevance to differentiating physiologic left ventricular hypertrophy from hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;51(23):2256–62.

    Article  PubMed  Google Scholar 

  11. Schnell F, Matelot D, Daudin M, et al. Mechanical dispersion by strain echocardiography: a novel tool to diagnose hypertrophic cardiomyopathy in athletes. J Am Soc Echocardiogr. 2017;30(3):251–61.

    Article  PubMed  Google Scholar 

  12. Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol. 2009;53(3):284–91.

    Article  PubMed  Google Scholar 

  13. Alpert C, Day SM, Saberi S. Sports and exercise in athletes with hypertrophic cardiomyopathy. Clin Sports Med. 2015;34(3):489–505.

    Article  PubMed  Google Scholar 

  14. Catto V, Dessanai MA, Sommariva E, Tondo C, Russo AD. S-ICD is effective in preventing sudden death in arrhythmogenic cardiomyopathy athletes during exercise. Pacing Clin Electrophysiol. 2019;42(9):1269–72.

    Article  PubMed  Google Scholar 

  15. Ullal AJ, Abdelfattah RS, Ashley EA, Froelicher VF. Hypertrophic cardiomyopathy as a cause of sudden cardiac death in the young: a meta-analysis. Am J Med. 2016;129(5):486–496.e482.

    Article  PubMed  Google Scholar 

  16. Cannan CR, Reeder GS, Bailey KR, Melton LJ 3rd, Gersh BJ. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation. 1995;92(9):2488–95.

    Article  CAS  PubMed  Google Scholar 

  17. Maron BJ, Rowin EJ, Casey SA, Garberich RF, Maron MS. What do patients with hypertrophic cardiomyopathy die from? Am J Cardiol. 2016;117(3):434–5.

    Article  PubMed  Google Scholar 

  18. Maron MS, Rowin EJ, Wessler BS, et al. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2019;4(7):644–57.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Reineck E, Rolston B, Bragg-Gresham JL, et al. Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy. Am J Cardiol. 2013;111(7):1034–9.

    Article  PubMed  Google Scholar 

  20. Masri A, Pierson LM, Smedira NG, et al. Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. Am Heart J. 2015;169(5):684–692 e681.

    Article  PubMed  Google Scholar 

  21. Sharma S, Elliott PM, Whyte G, et al. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol. 2000;36(3):864–70.

    Article  CAS  PubMed  Google Scholar 

  22. Sorajja P, Allison T, Hayes C, Nishimura RA, Lam CS, Ommen SR. Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2012;109(10):1494–8.

    Article  PubMed  Google Scholar 

  23. Bhella PS, Hastings JL, Fujimoto N, et al. Impact of lifelong exercise “dose” on left ventricular compliance and distensibility. J Am Coll Cardiol. 2014;64(12):1257–66.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Saberi S, Wheeler M, Bragg-Gresham J, et al. Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial. JAMA. 2017;317(13):1349–57.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Konhilas JP, Watson PA, Maass A, et al. Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ Res. 2006;98(4):540–8.

    Article  CAS  PubMed  Google Scholar 

  26. Dejgaard LA, Haland TF, Lie OH, et al. Vigorous exercise in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2018;250:157–63.

    Article  PubMed  Google Scholar 

  27. Klempfner R, Kamerman T, Schwammenthal E, et al. Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center. Eur J Prev Cardiol. 2015;22(1):13–9.

    Article  PubMed  Google Scholar 

  28. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation. 2009;119(8):1085–92.

    Article  PubMed  Google Scholar 

  29. Maron BJ, Klues HG. Surviving competitive athletics with hypertrophic cardiomyopathy. Am J Cardiol. 1994;73(15):1098–104.

    Article  CAS  PubMed  Google Scholar 

  30. Lampert R, Olshansky B, Heidbuchel H, et al. Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry. Circulation. 2013;127(20):2021–30.

    Article  PubMed  Google Scholar 

  31. Pelliccia A, Lemme E, Maestrini V, et al. Does sport participation worsen the clinical course of hypertrophic cardiomyopathy? Clinical outcome of hypertrophic cardiomyopathy in athletes. Circulation. 2018;137(5):531–3.

    Article  PubMed  Google Scholar 

  32. Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015;66(21):2362–71.

    Article  PubMed  Google Scholar 

  33. Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2019;40(1):19–33.

    Article  PubMed  Google Scholar 

  34. Writing Committee M, Ommen SR, Mital S, et al. AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):3022–55.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sports Cardiology Center, Hypertrophic Cardiomyopathy Center, Sanger Heart & Vascular Institute, Atrium Health, Charlotte, NC, USA

    Dermot M. Phelan & John Symanski

Authors
  1. Dermot M. Phelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Symanski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dermot M. Phelan .

Editor information

Editors and Affiliations

  1. Division of Cardiology, Columbia University Irving Medical Center, New York, NY, USA

    David J. Engel

  2. Sports Cardiology Center, Hypertrophic Cardiomyopathy Center Atrium Health Sanger Heart & Vascular Institute, Charlotte, NC, USA

    Dermot M. Phelan

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Phelan, D.M., Symanski, J. (2021). Hypertrophic Cardiomyopathy. In: Engel, D.J., Phelan, D.M. (eds) Sports Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-69384-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-69384-8_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-69383-1

  • Online ISBN: 978-3-030-69384-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation